SCHEMBL24253569

SCHEMBL24253569

CC(C)c1cc2nnccc2cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
SLC6A2 P23975 2/20 0.39
HTR2B P41595 2/20 0.39
TRPA1 O75762 1/20 0.39
CHRM1 P11229 1/20 0.39
ADRA1A P35348 1/20 0.39
GABRA1 P14867 3/20 0.34
GABRB2 P47870 3/20 0.34
HSP90AA1 P07900 8/20 0.34
HSP90AB1 P08238 7/20 0.34
MET P08581 1/20 0.34
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2B6 P20813 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
STAT3 P40763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24868665 0.93 LMNA (0.39) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL16744199 0.85 P2RX3 (0.32)
SCHEMBL28340678 0.79 EGFR (0.39) HPGDCYP2C9KDM4EALDH1A1GAA
SCHEMBL2961115 0.76 P2RX3 (0.49) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL25883685 0.75 MET (0.30) MET
SCHEMBL22792450 0.73
SCHEMBL25065503 0.73 KDM4E (0.40) TRPA1CYP3A4HPGDCYP2C9CYP2C19
SCHEMBL24925369 0.72 KDM4E (0.33) HPGDKDM4EALDH1A1GAASTAT3
SCHEMBL17885780 0.72 ALDH1A1 (0.47) LMNAHSP90AA1HSP90AB1CYP3A4HPGD
SCHEMBL24253452 0.70 RPS6KA3 (0.43) LMNASLC6A2HTR2BTRPA1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 LMNA 218/4885SLC6A2 4769/4885HTR2B 3833/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 LMNA 218/4885SLC6A2 4769/4885HTR2B 3833/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885SLC6A2 4676/4885HTR2B 4365/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.